Voice your opinion on congressional bill HR4629-116 and let lawmakers know your stance with UnPac!

Main Subject: Health

Star Rating for Biosimilars Act

This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish quality measures regarding biosimilar biological products under the five-star performance rating system for Medicare Advantage plans. The measures must assess the level of access that plans provide to covered biosimilars, including with respect to formularies, cost-sharing, and utilization management.

The CMS must also incorporate such measures into similar rating systems for plans under the Medicare prescription drug benefit.

HR3-116, S2543-116, S4199-116,

Library of Congress Actions

IntroReferral
Oct. 18 2019	Sponsor introductory remarks on measure. (CR H8232)
Oct. 08 2019	Introduced in House Introduced in House

House committee actions Actions

Committee
Oct. 09 2019	Referred to the Subcommittee on Health.
Oct. 08 2019	Referred to the Subcommittee on Health.

House floor actions Actions

IntroReferral

Oct. 08
2019

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

House bill HR4629-116

Star Rating for Biosimilars Act

Promote the cause!

Or use this QR code